UNSPSC 51142313: Nalorphine hydrobromide

This classification denotes a narcotic antagonist C20H23NO3.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1OLB66508A, chemically known as morphinan-3,6-.alpha.-diol, 17-allyl-7,8-didehydro-4,5-.alpha.-epoxy-, hydrobromide, but more generally known as nalorphine hydrobromide, which bears US NIH Compound Identifier 5486631. Most nations, for tariff and trade purposes, schedule nalorphine hydrobromide under HS 29391900 and SITC 54141. As of Q4 2014, NALORPHINE HYDROBROMIDE remains US FDA's Preferred Term for this commodity.

SMILES: COC1CCC2C3C1O[C@@H]4[C@]35CCN([C@H](C2)[C@@H]5C=C[C@@H]4O)CC=C.BR.

UNSPSC 51142313 Nalorphine hydrobromide is a Commodity code that in practice covers opioid antagonist pharmaceuticals and related drug management systems procured by state and local health agencies. Recent state and local solicitations show procurement focused on naloxone supply and safe drug deactivation systems to support community health and substance-abuse-response initiatives, rather than nalorphine hydrobromide specifically. Health departments, counties, and state pharmacy benefit programs are the primary issuing bodies, with activity spanning from individual county health systems to multistate cooperative purchasing alliances and state health and human services commissions. Procurement spans both emergency-supply acquisition for community health programs and wholesale distribution agreements for state and local pharmacy networks, including arrangements requiring FDA compliance, cGMP certification, and Drug Supply Chain Security Act adherence. Vendors must typically maintain insurance coverage including general liability and workers' compensation, comply with E-Verify requirements, and deliver products to specified locations on quarterly or scheduled bases.

Recent activity centers in Florida and the Upper Midwest. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with deliveries to the Seminole County Community Health Building, response due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, to establish contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities including Oregon, with proposals due March 26, 2026, and awarded vendors to be available by July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to explore direct-to-manufacturer prescription fulfillment models for therapeutic pharmacy initiatives, indicating early-stage strategic planning in that state. The code shows active procurement but primarily under broader pharmaceutical supply agreements rather than nalorphine hydrobromide as a named line item.